These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12635473)

  • 1. The economic burden of sepsis in Austria.
    Schmid A; Schneider H
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
    [No Abstract]   [Full Text] [Related]  

  • 2. [The incidence and cost of severe sepsis in intensive care units].
    Csomós A; Hoffer G; Fülesdi B; Ludwig E
    Orv Hetil; 2005 Jul; 146(29):1543-7. PubMed ID: 16136776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?
    Shorr AF; Micek ST; Jackson WL; Kollef MH
    Crit Care Med; 2007 May; 35(5):1257-62. PubMed ID: 17414080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics and outcome in the intensive care unit.
    Pittoni GM; Scatto A
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):232-6. PubMed ID: 19390250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary sepsis in a university hospital in northern Sweden: a retrospective study.
    Jacobson S; Johansson G; Winsö O
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):960-7. PubMed ID: 15315612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of intensive care unit-acquired bloodstream infections.
    Laupland KB; Lee H; Gregson DB; Manns BJ
    J Hosp Infect; 2006 Jun; 63(2):124-32. PubMed ID: 16621137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation of activated protein C treatment for severe sepsis.
    Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
    N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical imperative versus economic consequence: exploring the cost burden and opportunities in the care of patients with sepsis.
    Merritt CL
    Nurs Adm Q; 2011; 35(1):61-7. PubMed ID: 21157265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A method to determine hospital costs associated with nosocomial infections].
    Gianino MM; Vallino A; Anselmo E; Minniti D; Abbona F; Mineccia C; Silvaplana P; Zotti CM
    Ann Ig; 2007; 19(4):381-92. PubMed ID: 17937330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
    Chawla LS; Seneff MG; Nelson DR; Williams M; Levy H; Kimmel PL; Macias WL
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):22-30. PubMed ID: 17699383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.
    Burchardi H; Schneider H
    Pharmacoeconomics; 2004; 22(12):793-813. PubMed ID: 15294012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of bloodstream infections.
    Kilgore M; Brossette S
    Am J Infect Control; 2008 Dec; 36(10):S172.e1-3. PubMed ID: 19084149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysis.
    Rosenthal VD; Guzman S; Migone O; Crnich CJ
    Am J Infect Control; 2003 Dec; 31(8):475-80. PubMed ID: 14647110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost evaluation of patients with severe sepsis in intensive care units.
    Piacevoli Q; Palazzo F; Azzeri F
    Minerva Anestesiol; 2004 Jun; 70(6):453-71. PubMed ID: 15235553
    [No Abstract]   [Full Text] [Related]  

  • 17. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical-economic evaluation of severe sepsis].
    Guidet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
    [No Abstract]   [Full Text] [Related]  

  • 19. [Exogenous activated protein C in severe sepsis].
    Mamontova OA; Protsenko DN; Eliutin DV; Kirienko PN; Gel'fand BR
    Anesteziol Reanimatol; 2005; (3):42-5. PubMed ID: 16076046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates.
    Tacconelli E; Smith G; Hieke K; Lafuma A; Bastide P
    J Hosp Infect; 2009 Jun; 72(2):97-103. PubMed ID: 19246122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.